Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (111-120 of 269) with videos related to

Pageof 27
Sort By:
Journal of Crohn'S & Colitis|December 9, 2023
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 StudiesJean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, et al.
Annals of Internal Medicine|May 2, 2007
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialWilliam J Sandborn, Paul Rutgeerts, Robert Enns, et al.
Inflammatory Bowel Diseases|March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension studyBruce E Sands, David B Clemow, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 6, 2016
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND TrialWalter Reinisch, Jean-Frédéric Colombel, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-surveyPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Gastroenterology|September 25, 2012
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel diseaseGeert D'Haens, Brian Feagan, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis|January 13, 2021
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyWilliam J Sandborn, Brian G Feagan, Stephen Hanauer, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Gastroenterology|February 25, 2020
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative ColitisWilliam J Sandborn, Subrata Ghosh, Julian Panes, et al.
Journal of Crohn'S & Colitis|August 1, 2023
Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative ColitisVincent Joustra, Andrew Y F Li Yim, Sara van Gennep, et al.
Pageof 27

Showing results (111-120 of 269) with videos related to

Sort By:
Pageof 27
Journal of Crohn'S & Colitis|December 9, 2023
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 StudiesJean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, et al.
Annals of Internal Medicine|May 2, 2007
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialWilliam J Sandborn, Paul Rutgeerts, Robert Enns, et al.
Inflammatory Bowel Diseases|March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension studyBruce E Sands, David B Clemow, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 6, 2016
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND TrialWalter Reinisch, Jean-Frédéric Colombel, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-surveyPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Gastroenterology|September 25, 2012
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel diseaseGeert D'Haens, Brian Feagan, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis|January 13, 2021
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyWilliam J Sandborn, Brian G Feagan, Stephen Hanauer, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Gastroenterology|February 25, 2020
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative ColitisWilliam J Sandborn, Subrata Ghosh, Julian Panes, et al.
Journal of Crohn'S & Colitis|August 1, 2023
Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative ColitisVincent Joustra, Andrew Y F Li Yim, Sara van Gennep, et al.
Pageof 27